Eli Lilly and Co. (NYSE:LLY) revealed plans to inject an extra $4.5 billion into two of its Indiana manufacturing sites on Wednesday. This move escalates its total capital expansion in the state since 2020 to over $21 billion.
The additional funding is intended to support the production of Foundayo, Lilly’s newly approved weight-loss pill, and retatrutide, an obesity treatment in late-stage development.
The new investment would introduce advanced process designs and technologies at one of Lilly’s upcoming active pharmaceutical ingredient (API) facilities, as well as at its first dedicated genetic medicine manufacturing plant. The newly launched Lebanon Advanced Therapies facility would handle both clinical and commercial production of genetic medicines, supporting everything from early-stage research to large-scale commercial manufacturing.
CEO David Ricks said that Lilly’s Lebanon API facility, set to open in 2027, will become the largest API production site in U.S. history and reflects the company’s commitment to expanding manufacturing domestically. Since 2020, Lilly has committed more than $50 billion to expanding its U.S. manufacturing footprint and plans to begin construction on several newly announced facilities this year.
The Trump Factor
Global drugmakers have increased U.S. manufacturing and stockpiled inventory as the Trump administration pushes for 100% tariffs on branded drugs unless companies lower prices or shift production domestically under its “Most Favored Nation” pricing policy.
Major pharmaceutical companies including Pfizer Inc. (NYSE:PFE), Eli Lilly and Co., AstraZeneca PLC (NYSE:AZN), Novo Nordisk (NYSE:NVO), and Johnson & Johnson (NYSE:JNJ) secured three-year exemptions from the tariffs, with J&J also committing $55 billion toward U.S. investments and two new manufacturing facilities.
On Wednesday, President Donald Trump also shared the news about Eli Lilly’s additional Indiana investment on his Truth Social Platform.
Foundayo Fuels Lilly Growth Hopes
This announcement comes on the heels of the Food and Drug Administration (FDA) approving Foundayo for adults with obesity or those who are overweight with related health conditions. The once-daily GLP-1 pill can be taken without food or water restrictions, offering a more convenient alternative to injectable weight-loss treatments.
Furthermore, Eli Lilly’s revenue surged 56% year-over-year to $19.8 billion during its first-quarter 2026, primarily driven by the astronomical demand for its metabolic and weight-management medications. According to Gary Black, Managing Partner of The Future Fund, said that Foundayo could be the company’s “biggest drug yet.”
Factoring in a 27x projected 2026 price-to-earnings ratio, along with expected long-term revenue growth of 15% and earnings-per-share growth of 20%, Black said Eli Lilly’s valuation remains attractive.
However, a Deloitte report revealed that the pharmaceutical industry is currently facing a potential “bubble effect” due to the rising demand for weight-loss and diabetes drugs. This shift heightens companies’ susceptibility to therapeutic-area-specific shocks.
LLY Price Action: Over the past month, Eli Lilly shares gained 6.01%, according to Benzinga Pro. On Wednesday, they edged 0.18% lower to close at $987.05.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Recent Comments